Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original): A compound of formula I



I

wherein

R_a is H; C_{1-4}alkyl; or C_{1-4}alkyl substituted by OH, NH_2, NHC_{1-4}alkyl or $N(di\text{-}C_{1-4}alkyl)_2$;

one of R_b, R_c, R_d and R_e is halogen; C_{1-4}alkoxy; or C_{1-4}alkyl; and the other three substituents are H; or R_b, R_d and R_e are all H; and

R is a radical of formula (a)



(a)

wherein

R_1 is $-(CH_2)_n-NR_3R_4$, wherein

each of R_3 and R_4, independently, is H or C_{1-4}alkyl; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue;

n is 0, 1 or 2; and

R_2 is H; halogen; C_{1-4}alkyl; CF_3; OH; SH; NH_2; NO_2; C_{1-4}alkoxy; C_{1-4}alkylthio; NHC_{1-4}alkyl; $N(di\text{-}C_{1-4}alkyl)_2$ or CN;

or a salt thereof.

Claim 2. (Original): A compound according to claim 1 wherein R_a is H or methyl; one of R_b, R_c, R_d and R_e is methyl or ethyl and the other three substituents are H; or R_b, R_c, R_d and R_e are all H; R_2 is H; Cl, methyl or NO_2; n is 1; and each of R_3 and R_4, independently, is H, methyl, ethyl or *i*-propyl; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue, or a salt thereof.

Claim 3. (Currently amended): A compound according to claim 1 ~~or 2~~ which is selected from 3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro 6-methylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-methylaminomethyl -naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; or a salt thereof.

Claim 4. (Currently amended): A compound according to ~~any one of~~ claim 1 ~~to 3~~, in free form or in a pharmaceutically acceptable salt form, for use as a pharmaceutical.

Claims 5. and 6. (Canceled)

Claim 7. (Currently amended): Use of a compound according to ~~any one of~~ claim 1 ~~to 3~~, in free form or in a pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 5 in the manufacture of a medicament for treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection, cancer or infectious diseases.

Claim 8. (Currently amended): A pharmaceutical combination comprising a compound according to ~~any one of~~ claim 1 ~~to 3~~, in free form or in a pharmaceutically acceptable salt form, and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic, antiproliferative and anti-diabetic agents.

Claim 9. (Currently amended): A process for the production of the compound of formula I according to claim 1 ~~or claim 2~~, which process comprises reacting a compound of formula II



II

wherein R_a ; R_b; R_c, R_d and R_e are as defined in claim 1 ~~and claim 2~~, with a compound of formula III

$$R - CH_2 - CO - NH_2 \qquad (III)$$

wherein R is as defined in claim 1 and claim 2,

and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

Claim 10. (Currently amended): A method for treating or preventing disorders or diseases mediated by T lymphocytes and/or PKC, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to ~~any one of~~ claim 1 ~~to 3~~, or a pharmaceutically acceptable salt thereof.